Results 161 to 170 of about 1,925 (192)

RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing

Pediatrics
BACKGROUND Data describing respiratory syncytial virus (RSV) neutralizing antibody (nAb) levels for nirsevimab, a recently approved, extended half-life, anti-RSV fusion protein (F protein) monoclonal antibody, relative to the previous standard of care, palivizumab ...
Deidre, Wilkins, Ulrika, Wählby Hamrén, Yue, Chang, Lindsay E, Clegg, Joseph, Domachowske, Janet A, Englund, William J, Muller, Amanda, Leach, Elizabeth J, Kelly, Tonya, Villafana   +9 more
openaire   +2 more sources

Nirsevimab and Acute Bronchiolitis Episodes in Pediatric Emergency Departments

Pediatrics
BACKGROUND AND OBJECTIVES In the 2023–2024 respiratory syncytial virus (RSV) season, Spain became one of the first countries to introduce universal RSV prophylaxis, during which all infants born at this time were eligible to receive nirsevimab. Locally, most Spanish
Andina Martinez, David, Claret Teruel, Gemma, Gijon Mediavilla, Manuel, Camara Otegui, Amaia, Banos Lopez, Laura, de Miguel Lavisier, Begona, Ferrero Garcia-Loygorri, Clara, Sanchez Tatay, Victoria, Pavlovic Nesic, Svetlana, Clerigue Arrieta, Nuria, Gimeno-Hernandez Garza, Veronica, Guerra Diez, Jose Lorenzo, Ranera Malaga, Adrian, Escalada Pellitero, Silvia, Barrueco Ramos, Clara, Alonso-Cadenas, Jose Antonio   +15 more
openaire   +3 more sources

Safety of timely immunization with nirsevimab in hospitalized preterm infants

Vaccine
We aimed to assess the safety profile of nirsevimab in hospitalized preterm infants (PT). We conducted an observational, uncontrolled, prospective study in clinically stable PT admitted to the neonatal unit. One hundred and ten PT were eligible for immunization; uptake was 93.5 % (n = 103) (median GA and BW of 33 weeks and 1892 g, respectively), and a ...
Giannina, Izquierdo, Rodolfo, Villena, Camila, Cabrera, Javiera, Albornoz, Natalie, Hueichao, Carolina, Guerra, Juan Pablo, Torres   +6 more
openaire   +2 more sources

Nirsevimab Effectiveness at Preventing RSV-Related Hospitalization in Infants

NEJM Evidence
In pivotal trials, nirsevimab showed promising efficacy in reducing hospitalizations for respiratory syncytial virus-associated lower respiratory tract infections (RSV-LRTIs). Nirsevimab's real-world effectiveness needs to be assessed.This population-based study used the French National Health Data System.
Marie Joelle, Jabagi, Jérémie, Cohen, Marion, Bertrand, Martin, Chalumeau, Mahmoud, Zureik   +4 more
openaire   +2 more sources

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

New England Journal of Medicine, 2022
Ron Dagan, Shabir A Madhi, William J Müller   +2 more
exaly  

New drug: nirsevimab

Ge-Bu, 2023
openaire   +1 more source

Nieuw geneesmiddel: nirsevimab

Ge-Bu, 2023
openaire   +1 more source

Nirsevimab: The Hidden Costs

Hospital Pediatrics
Samantha, Neumann, Brian, Alverson
openaire   +2 more sources

Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study

The Lancet Regional Health Americas, 2023
Affan Shoukat, Alison P Galvani, Scott A Halperin   +2 more
exaly  

Nirsevimab-resistant respiratory syncytial virus strains are rare but there

The Lancet Infectious Diseases, 2023
Mark E, Peeples, Ilada, Thongpan
openaire   +2 more sources